ellaOne 30 mg 挪威 - 挪威文 - Statens legemiddelverk

ellaone 30 mg

2care4 - ulipristalacetat - tablett - 30 mg

Maasol - 挪威 - 挪威文 - Statens legemiddelverk

maasol -

ge healthcare as - albumin humant serum makroaggregater ad tc-99m makroalbumin - pulver til injeksjonsvæske, suspensjon

Nanocoll - 挪威 - 挪威文 - Statens legemiddelverk

nanocoll -

ge healthcare as - albumin humant kolloidale partikler ad tc-99m albumin nanokolloid - pulver til injeksjonsvæske, suspensjon

Ovitrelle 250 mikrog 挪威 - 挪威文 - Statens legemiddelverk

ovitrelle 250 mikrog

2care4 aps - koriongonadotropin alfa - injeksjonsvæske, oppløsning - 250 mikrog

Primolut N 5 mg 挪威 - 挪威文 - Statens legemiddelverk

primolut n 5 mg

bayer ab - solna - noretisteron - tablett - 5 mg

Crysvita 欧盟 - 挪威文 - EMA (European Medicines Agency)

crysvita

kyowa kirin holdings b.v. - burosumab - hypophosphatemia, familial; hypophosphatemic rickets, x-linked dominant; osteomalacia - legemidler til behandling av bein sykdommer - crysvita is indicated for the treatment of x-linked hypophosphataemia, in children and adolescents aged 1 to 17 years with radiographic evidence of bone disease, and in adults. crysvita is indicated for the treatment of fgf23-related hypophosphataemia in tumour-induced osteomalacia associated with phosphaturic mesenchymal tumours that cannot be curatively resected or localised in children and adolescents aged 1 to 17 years and in adults.

Sodium Iodide [131I] Diagnostic Capsules GE Healthcare 3.7 MBq 挪威 - 挪威文 - Statens legemiddelverk

sodium iodide [131i] diagnostic capsules ge healthcare 3.7 mbq

ge healthcare buchler gmbh & co. kg - natriumjodid (131i) - kapsel, hard - 3.7 mbq

Theracap 131TM - 挪威 - 挪威文 - Statens legemiddelverk

theracap 131tm -

ge healthcare buchler gmbh & co. kg - natriumjodid (131i) - kapsel, hard

Bylvay 欧盟 - 挪威文 - EMA (European Medicines Agency)

bylvay

albireo - odevixibat - cholestasis, intrahepatic - galle- og leverterapi - bylvay is indicated for the treatment of progressive familial intrahepatic cholestasis (pfic) in patients aged 6 months or older (see sections 4. 4 og 5.

Evkeeza 欧盟 - 挪威文 - EMA (European Medicines Agency)

evkeeza

ultragenyx germany gmbh - evinacumab - hyperkolesterolemi - lipid modifiserende midler - evkeeza is indicated as an adjunct to diet and other low-density lipoprotein-cholesterol (ldl-c) lowering therapies for the treatment of adult and adolescent patients aged 12 years and older with homozygous familial hypercholesterolaemia (hofh).